Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (2019 - 2025)

Historic Shares Outstanding for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $74.2 million.

  • C4 Therapeutics' Shares Outstanding rose 511.83% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 511.83%. This contributed to the annual value of $70.6 million for FY2024, which is 1680.04% up from last year.
  • C4 Therapeutics' Shares Outstanding amounted to $74.2 million in Q3 2025, which was up 511.83% from $71.0 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Shares Outstanding peaked at $74.2 million during Q3 2025, and registered a low of $43.1 million during Q1 2021.
  • For the 5-year period, C4 Therapeutics' Shares Outstanding averaged around $57.2 million, with its median value being $49.1 million (2023).
  • As far as peak fluctuations go, C4 Therapeutics' Shares Outstanding surged by 314625.18% in 2021, and later skyrocketed by 38.35% in 2023.
  • Over the past 5 years, C4 Therapeutics' Shares Outstanding (Quarter) stood at $48.7 million in 2021, then grew by 0.57% to $49.0 million in 2022, then grew by 23.49% to $60.5 million in 2023, then rose by 16.8% to $70.6 million in 2024, then grew by 5.02% to $74.2 million in 2025.
  • Its Shares Outstanding stands at $74.2 million for Q3 2025, versus $71.0 million for Q2 2025 and $71.0 million for Q1 2025.